[ad_1]
(WPRI) – The US Food and Drug Administration sent an alert this week about some forms of flea and tick treatment.
According to the agencysome treatments in the isoxazoline class may cause neurological side effects.
"Some animals receiving Bravecto, Nexgard or Simparica have experienced adverse events such as muscle tremors, ataxia and seizures," the FDA said in a statement. The agency also named Credelio, who is in this class and has just received FDA approval.
The FDA has stated that products – used for the treatment and control of tick infestations – continue to be safe for the majority of animals.
The agency is asking manufacturers to make product labeling changes to provide veterinarians and pet owners with the information they need to make treatment decisions for the company. each animal on an individual basis.
To report suspected adverse events related to these products and / or obtain a copy of the SDS or for technical assistance, contact the affected manufacturers at the following phone numbers:
Merck Animal Health (Bravecto): 800-224-5318
Animal Health Elanco (Credelio): 888-545-5973
Merial (Nexgard): 888-637-4251
Zoetis (Simparica): 888-963-8471
If you prefer to report directly to the FDA, or if you would like more information on reporting side effects of animal medications, refer to How to Report Side Effects and Problems with Animal Products.
FDA Information Sheet »
Source link
